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Abstract
Background: BRCA1 and BRCA2 mutations are found in a proportion of families with multiple early-onset breast
cancers. There are a large number of different deleterious mutations in both genes, none of which would be
detectable using standard genetic association studies. Single common variants and haplotypes of common variants
may capture groups of deleterious mutations since some low prevalence haplotypes of common variants occur
more frequently among chromosomes that carry rare, deleterious mutations than chromosomes that do not.
Methods: DNA sequence data for BRCA1 and BRCA2 was obtained from 571 participants from the Australian Breast
Cancer Family Study. Genetic variants were classified as either deleterious mutations or common genetic variants.
Variants tagging common polymorphisms were selected and haplotypes resolved using Haploview. Their frequency
was compared to those with and without deleterious mutations using a permutation test.
Results: A common genetic variant in BRCA1 (3232A > G) was found to be over-represented in deleterious
mutation carriers (p = 0.05), whereas a common genetic variant in BRCA2 (1342A > C) occurred less frequently in
deleterious mutation carriers (p = 0.04). All four of the common BRCA1 variants used to form haplotypes occurred
more frequently in the deleterious mutation carriers when compared to the non-carriers, but there was no
evidence of a difference in the distributions between the two groups (p = 0.34). In BRCA2, all four common
variants were found to occur less frequently in the deleterious mutation carriers when compared to non-carriers,
but the evidence for difference in the distribution between the two groups was weak (p = 0.16). Several less
common haplotypes of common BRCA1 variants were found to be over-represented among deleterious mutation
carriers but there was no evidence for this at the population level. In BRCA2, only the most common haplotype
was found to occur more frequently in deleterious mutation carriers, with again no evidence at the population
level.
Conclusions: We observed differences in the frequency of common genetic variants of the BRCA1 and BRCA2 and
their haplotypes between early-onset breast cancer cases who did and did not carry deleterious mutations in these
genes. Although our data provide only weak evidence for a difference in frequencies at the population level, the
number of deleterious mutation carriers was low and the results may yet be substantiated in a larger study using
pooled data.
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Mutations in BRCA1 and BRCA2 are found in a propor-
tion of multiple case breast cancer families. The particu-
lar mutations that are present differ from family to
family indicating the marked allelic heterogeneity of
these genes. The only viable methods for the identifica-
tion of mutations in genes prone to such variation are
sequencing or extensive DNA screening techniques.
Mutation screening of these genes has become wide-
spread despite the costs involved. In fact, 890 and 975
non-protein truncating mutations have been identified
in BRCA1 and BRCA2 respectively, making it difficult to
identify causal mutations due to the large number of
variants. Many such variants may appear deleterious but
may nevertheless only be associated with disease
because they are close to a causal mutation and not
deleterious in their own right. An appealing strategy is
therefore to avoid the large number of comparisons
required to test each variant separately, but to instead
use methods based on haplotypes, which are combina-
tions of genetic variants or alleles (typically common
polymorphisms) inherited together or in phase from a
single parent. They result from the phenomenon of link-
age disequilibrium (LD), where alleles at closely spaced
markers do not segregate independently. Haplotypes can
capture more information across genomic regions of
interest on the human genome than is available by
examining single genetic markers one at a time [1] how-
ever the generation of haplotypes is difficult, usually
requiring intensive laboratory efforts or the collection
and genotyping of several closely related relatives to
infer phase. An alternative is to infer phase from geno-
type data using the statistical techniques that have been
developed rapidly in the last few years, which is the
approach adopted in this report.
Haplotypes are expected to play an important role in
the fine mapping of complex diseases since disease-
affected individuals with common haplotypes may have
recent shared ancestry of chromosomal segments that
harbour disease-causing variants [2]. By identifying “dis-
ease haplotypes” that are the hallmarks of deleterious
BRCA1 and BRCA2 mutations, it may be possible to
identify carriers implicitly rather than by screening of
the entire gene. Some early work in this area has sug-
gested that one haplotype in BRCA1 is over-represented
in individuals carrying deleterious mutations [3] while
another haplotype was associated with a 20% increased
risk in breast cancer [4]. There is evidence that this sce-
nario is particularly useful for common polymorphisms
of low penetrance, where results show that an associa-
tion can be detected via haplotype methods using single
nucleotide polymorphisms surrounding the functional
allele even if the functional allele is not typed [5]. We
explored extending this approach to detecting rare dele-
terious mutations, which are likely to have arisen more
recently and occur on extended, less common
haplotypes.
Methods
Study Methods
The Australian Breast Cancer Family Study (ABCFS)
[6,7] is a population based case-control-family study car-
ried out in the metropolitan areas of Melbourne and
Sydney between years 1992 and 1999. Potential case
patients were identified through the Victorian and New
South Wales cancer registries. Women were eligible if
they were aged between 18 and 59 and had been diag-
nosed with histologically confirmed first primary cancer
of the breast, irrespective of family history of breast can-
cer. Controls were women with no previous breast can-
cer, randomly selected from the electoral roll for which
registration (and voting) is compulsory in Australia. Let-
ters to cases were sent to both the attending doctor and
patient inviting them to participate. Participation
involved completing an interviewer administered risk
factor questionnaire and giving a blood sample. A
detailed family history was recorded for all first-degree
and second-degree relatives, with verification sought for
all reports of cancers in other family members. All
patients provided written informed consent for partici-
pation in all aspects of the study. Sampling of cases was
stratified by the age of onset, with over half being less
than 40 years old. The majority of proband participants
in the ABCFS are white women with northern or south-
ern European ancestry. The protocols for ABCFS have
been approved by the Human Research Ethics Commit-
tee of University of Melbourne. Details of recruitment
strategy, participation, and data collection methods have
previously been described [6].
Molecular methods
The coding and exon flanking sequences of BRCA1 and
BRCA2 were screened as described in [7]. These ana-
lyses were performed by Myriad Genetic Laboratories,
Inc. using full sequence analyses (BRC-Analysis), in
house DNA sequencing and 2 D gel electrophoresis,
which are fully described in [8,9].
The criteria for defining deleterious mutations were
those used by the Breast Information Core (BIC; http://
research.nhgri.nih.gov/bic/ and Myriad Genetic Labora-
tories, Inc. and are described in more detail in [9].
Statistical methods
A smaller set of haplotype tagging SNPs (htSNP) was
identified to explain the diversity of common haplotypes
[10] using the Haploview software [11]. Haploview was
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BRCA1 and BRCA2 from the data. Haploview uses a
two marker EM algorithm (ignoring missing data) to
estimate the maximum-likelihood values of the four
gamete frequencies, from which the calculations for the
LD summary statistics D’ (Lewontin’s normalized coeffi-
cient D’ [12]), LOD (likelihood ratio test statistic) and r
2
(paired correlation) are derived. Haplotype phase and an
estimate of the population frequency distribution of the
haplotypes are inferred using a standard EM algorithm
with a partition-ligation approach for blocks with
greater than 10 markers. The standard chi-squared
statistics on 1 degree of freedom and a corresponding
p-value to test the assumption of Hardy-Weinberg Equi-
librium (HWE) values were also generated for each
variant using Haploview.
To validate the calculations in Haploview, haplotypes
of tag SNPs were also generated using the Bayesian
simulation procedures incorporated in the PHASE soft-
ware [13,14], which implements a Markov chain Monte
Carlo (MCMC) algorithm. One advantage of this alter-
native software is that it can be used to generate stan-
dard errors for estimates of the population haplotype
frequencies. We compared those standard errors to
these generated from the sampling variability of a pro-
portion using the binomial distributions and found that
they were undistinguishable so we present the latter
values based on the Haploview output only.
Individuals were classified into two groups according to
whether their DNA specimen results showed that they
had at least one deleterious mutation in BRCA1 and
BRCA2 or not. Estimated frequencies of haplotypes as
well as individual htSNP were compared between indivi-
duals carrying and not carrying deleterious mutations
using the permutation test (with 10000 permutations) for
association between SNP and case/control status that is
implemented in Haploview. Haplotype distributions were
also compared between groups with and without deleter-
ious mutations by (i) using the permutation p-value for
each single haplotype to generate a chi-squared statistic
on 1 degree of freedom and then (ii) summing the chi-
squared statistics to generate a combined statistics which
was then compared to the chi-squared distribution with
the relevant number of degrees of freedom to generate a
p-value. These p-values were compared to the p-value
generate by PHASE for comparing the full haplotype dis-
tribution. We found that in all cases these procedures
gave the same “omnibus” p-value to two decimal places,
which provides an empirical validation of the procedure
used in PHASE.
Results
Data was available on 680 participants in regard to
BRCA1 and 245 participants for BRCA2 (table 1).
Analyses was restricted to the 392 (BRCA1)a n d1 7 9
(BRCA2) population-based individuals diagnosed with a
first primary invasive breast cancer before 40 years of
age for whom BRCA1 and BRCA2 had been sequenced.
Some sequencing was performed for cases in other age
groups but the sample sizes were small and not suffi-
cient to warrant separate analysis. The total number of
variants found in the coding regions of BRCA1 and
BRCA2 gene in cases under 40 were 22 (table 2) and 15
(table 3) respectively. Each of the deleterious mutations
identified in our sample appeared only once, with the
exception of 2800 del AAG which occurred once in
each of two study participants.
Tables 4 and 5 list the details of the variants selected
as tagSNPs by Haploview’s Tagger program for BRCA1
and BRCA2 respectively. These tables display results of
Table 1 Breast cancer cases with DNA sequence data and
those carrying deleterious mutations by age group
Age BRCA1 total
with sequenced
data
BRCA1
deleterious
mutation
number
BRCA2 total
with sequenced
data
BRCA2
deleterious
mutation
number
<40 392 13 179 11
40-49 102 4 34 0
50-59 186 1 32 0
Total 680 18 245 11
Table 2 Observed BRCA1 variants in breast cancer cases
diagnosed before age 40 in the ABCFS
Variant rs
number
Codon MAF HWE Deleterious
mutation?
188 del 11 C24X 0.001 1.000 Yes
189 del 11 0.003 1.000 Yes
546 G > T E143X 0.001 1.000 Yes
1186 A > G rs1799950 Q356R 0.056 0.557 No
1876 del C 0.001 1.000 Yes
2196 G > A rs4986850 D693N 0.060 0.461 No
2201 C > T rs1799949 S694S 0.227 0.000 No
2430 T > C rs16940 L771L 0.218 0.000 No
2594 del C 0.001 1.000 Yes
2731 C > T rs799917 P871L 0.231 0.000 No
2800 del AAG 0.001 1.000 Yes
3232 A > G rs16941 E1038G 0.195 0.000 No
3415 del C 0.001 1.000 Yes
3667 A > G rs16942 K1183R 0.231 0.000 No
3875 del GTCT 0.001 1.000 Yes
3888 del GAG 0.001 1.000 Yes
4184 del TCAA 0.003 1.000 Yes
4427 T > C rs1060915 S1436S 0.231 0.000 No
4446 C > T rs41293455 R1443X 0.001 1.000 Yes
4808 C > G Y1563X 0.001 1.000 Yes
4956 A > G rs1799966 S1613G 0.237 0.000 No
5382 ins C 0.003 1.000 Yes
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between individuals carrying and not carrying deleter-
ious mutations. In both BRCA1 and BRCA2 there was
some evidence that the tagSNPs allele frequency differed
according to deleterious mutation status. Genotype fre-
quencies for some variants generate small p-value for
t h et e s to fH W E ,m o s tl i k e l yd u et ot h ef a c tt h a to u r
analysis is restricted to breast cancer cases under age 40
years. The BRCA1 variant 3232A > G was found to
occur more frequently in deleterious mutation carriers
(p = 0.047) while BRCA2 variant 1342A > C was found
to occur less frequently in deleterious mutation carriers
(p = 0.043).
All four common BRCA1 variants used to form hap-
lotypes occur more frequently in the deleterious muta-
tion carriers when compared to the non-carrier group,
but there was no evidence of a difference in the distri-
bution between the two groups (p = 0.34). The oppo-
site was true for BRCA2, where all four common
variants were found to occur less frequently in the
deleterious mutation carriers group when compared to
non-carriers, but the evidence for difference in the
distribution between the two groups was weak (p =
0.16).
When comparing haplotype frequencies between the
two groups (tables 6 and 7), there was very weak evidence
that haplotype AGGT in BRCA1 was over-represented in
individuals carrying deleterious mutations (p = 0.151).
Overall, there was no evidence of difference between
haplotype distributions between deleterious mutation
carriers and non-carriers in BRCA1 (with 6.d.f., p =
0.717).The most common haplotype in BRCA2, AATA,
was also found to occur slightly more frequently in dele-
terious mutation carriers (p = 0.158). Again, there was no
evidence of difference in BRCA2 haplotype distributions
between the two groups (with 6.d.f., p = 0.851).
Discussion
In this paper we used BRCA1 and BRCA2 sequence data
from Australian breast cancer cases less than 40 years of
age at the time of diagnosis to classify individuals
according to their deleterious mutation status, and
resolved haplotypes of common polymorphisms sepa-
rately in the groups that did and did not carry deleter-
ious mutations.
We found weak evidence that one haplotype of
BRCA1 variants is over-represented in carriers of dele-
terious mutations. This haplotype contains the minor
allele for 3232A > G variant which we found to be over-
represented among deleterious mutation carriers. Other
haplotypes containing the minor allele “G” also occurred
more frequently in deleterious mutation group.
In BRCA2 we found evidence that the population fre-
quency of the most common haplotype in individuals
carrying deleterious mutations was greater than 95%,
when the corresponding frequency in those without
deleterious mutations was only 65%. Individuals without
this haplotype are unlikely to carry deleterious muta-
tions but the predictive power of this haplotype for dele-
terious mutations is low since it occurs very frequently
in those with no deleterious mutations (namely the vast
majority of the population).
The sample size of the deleterious mutation group was
small for both genes, with only 13 and 11 individuals
carrying deleterious mutations for BRCA1 and BRCA2
Table 3 Observed BRCA2 variants in breast cancer cases
diagnosed before age 40 in the ABCFS
Variant rs number Codon MAF HWE Deleterious
mutation?
478 C > T Q84X 0.003 1.000 Yes
1342 A > C rs6004238 N372H 0.318 0.000 No
3642 A > G rs1801406 K1132K 0.131 0.033 No
4035 T > C rs543304 V1269V 0.117 0.038 No
4075 del GT 0.003 1.000 Yes
4856 del A 0.003 1.000 Yes
5638 del GT 0.003 1.000 Yes
5803 del ATTA 0.003 1.000 Yes
6174 del T 0.003 1.000 Yes
6503 del TT 0.006 1.000 Yes
7405 ins A 0.003 1.000 Yes
7470 A > G rs1799955 S2414S 0.103 0.050 No
9097 C > T Q2957X 0.003 1.000 Yes
9132 del C 0.003 1.000 Yes
9504 T > G T3092X 0.003 1.000 Yes
Table 4 Comparison of individual BRCA1 variant frequencies
Variant rs number Codon
Change
Deleterious
mutation
non-
carriers
Deleterious
mutation
carriers
Chi square
(Permutation)
P value
(Permutation)
1186 A > G rs1799950 Q356R 0.054 0.107 0.180 0.671
2196 G > A rs4986850 D693N 0.060 0.071 0.000 1.000
3232 A > G rs16941 E1038G 0.189 0.357 3.945 0.047
4427 T > C rs1060915 S1436S 0.228 0.321 0.146 0.702
Overall 4.541 0.338
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t y p ef r e q u e n c i e si st h e r e f o re quite low, which might
explain some of the high p-values obtained from permu-
tation testing.
Our selection of tagSNPs for BRCA1 gene has one in
common with tagSNPs selection of Osorio et al. [3]
(where they have used 4427T- > C as a tagSNP) and
C o xe ta l .[ 4 ]( Q 3 5 6 Ra sat a g S N P ) .I nO s o r i oe ta l .
their class II haplotype occurs more frequently among
BRCA1 mutation carriers. This haplotype is essentially
characterized by the 4427C- > T variant allele which
was used as a tagSNP in our study. We found that
minor allele occurred more frequently in deleterious
mutation carriers compared to non-carriers (32% vs
23%) but the evidence for this at the population level
was weak p = 0.25. Cox et al. found slight increase in
risk of breast cancer with the Q356R polymorphism,
contradicting an earlier result showing an inverse asso-
ciation [15]. We found that Q356R occurred more fre-
quently among deleterious mutation carriers but again
the evidence at the population level was weak.
There have been several case control studies seeking
BRCA1 and BRCA2 variants associated with an
increased risk of breast cancer. Freedman at al. [16]
investigated if common BRCA2 variants contribute to
the more common forms of breast cancer in a large
multiethnic cohort. Twenty one tagging SNPs were
selected to predict common BRCA2 haplotypes. A num-
ber of haplotypes were found to be associated with
increased risk of breast cancer, all of which could be
attributed to a single marker (intron 24: rs206340) that
was not selected as a tag SNP for analysis in our study.
Freedman at al. [17] repeated similar analysis on BRCA1
gene. Specifically, they have used 28 variants to define
patterns of common variation (5 in common with var-
iants used in our study: Q356R, P871L, K1183R, S1613G
and E1038G). They found no evidence for significant
association between common variation in BRCA1 and
risk of breast cancer.
The suggestive associations that we have observed do
not imply a physical association on the same chromo-
some (as would be the case if the rare, deleterious muta-
tion was in cis phase with a haplotype consisting of, for
example, the minor alleles of several common variants)
or a functional association (as might be the case even if
the rare, deleterious mutation was in trans phase with a
common variant haplotype, since it may still act to
modify the penetrance of the disease causing variant).
Establishing the phase of rare, deleterious mutations and
the common variants we used to define haplotypes for
both BRCA1 and BRCA2 would require either a much
larger sample size than was available for this study,
genetic data from extended pedigrees or expensive
laboratory investigation.
Conclusions
We found some evidence that a single common BRCA1
variant occurs more frequently in deleterious mutation
carriers. All four common variants used to form BRCA1
haplotypes are over represented in deleterious mutation
carriers so the frequency of less common haplotypes is
also greater in this group but there is no evidence for
Table 5 Comparison of individual BRCA2 variant frequencies
Variant rs number Codon
Change
Deleterious
mutation
non-carriers
Deleterious
mutation
carriers
Chi square
(Permutation)
P value
(Permutation)
1342 A > C rs6004238 N372H 0.338 0.042 4.095 0.043
3642 A > G rs1801406 K1132K 0.141 0.000 1.392 0.238
4035 T > C rs543304 V1269V 0.123 0.042 0.215 0.643
7470 A > G rs1799955 S2414S 0.111 0.000 0.845 0.358
Overall 6.547 0.162
Table 6 Comparison of individual BRCA1 haplotype frequencies
Haplotype Deleterious mutation noncarriers
(standard error)
Deleterious mutation carriers
(standard error)
All
(standard error)
Chi square
(Permutation)
P value
(Permutation)
AATA 0.659 (0.025) 0.958 (0.011) 0.679 (0.025) 1.993 0.158
AGTG 0.003 (0.003) 0.000 (0.000) 0.003 (0.003) 0.000 1.000
CATA 0.078 (0.014) 0.000 (0.000) 0.073 (0.014) 0.205 0.651
CACA 0.119 (0.017) 0.042 (0.011) 0.114 (0.017) 0.044 0.833
CACG 0.003 (0.003) 0.000 (0.000) 0.003 (0.003) 0.000 1.000
CGTA 0.033 (0.009) 0.000 (0.000) 0.031 (0.009) 0.012 0.911
CGTG 0.104 (0.016) 0.000 (0.000) 0.097 (0.016) 0.394 0.530
Overall 2.648 0.851
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evidence that a single common variant is under-repre-
sented in deleterious mutation carriers so the most
common BRCA2 haplotype occurs more frequently in
this group. All four common variants used to form
BRCA2 haplotypes occur less frequently in deleterious
mutation carriers. We found no evidence of difference
in haplotype distributions between the two groups in
both genes, which concords with previous research.
These findings are unlikely to have implications for
screening at the population level for BRCA1 or BRCA2.
Abbreviations
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